$270.47
Value $652B
JNJ and LGND stock compared: price, dividend, valuation and results, from SEC filings.
$270.47
Value $652B
$286.85
Value $5.7B
Johnson & Johnson (JNJ) has a market value of $652B and Ligand Pharmaceuticals (LGND) $5.7B. Over the last year, with dividends, JNJ moved +36.6% and LGND +39.2%. The P/E is 40.5 for JNJ and 111.2 for LGND. Dividend yield: JNJ 1.95%, LGND none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
JNJ$652B
LGND$5.7B
JNJ is 114 times LGND
Revenue, 12 months
JNJ$99.3B
LGND$254M
JNJ is 391 times LGND
Net income, 12 months
JNJ$16.1B
LGND$51M
JNJ is 313 times LGND
Operating margin
JNJ–
LGND9.3%
ROIC
JNJ12.4%
LGND1.3%
11.1 points apart
P/E
JNJ40.5
LGND111.2
LGND is 2.7 times JNJ
Dividend yield
JNJ2.0%
LGND0.0%
2.0 points apart
5-year return
JNJ+90.9%
LGND+184.0%
93.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
JNJ+90.9%
LGND+184.0%
| Period | JNJWith dividends | LGNDWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | +36.6%Price +33.6% | +39.2%Price +39.2% |
| 3 years since November 20, 2023 | +94.9%+24.9% a yearPrice +80.4% | +393.5%+70.3% a yearPrice +393.5% |
| 5 years since November 19, 2021 | +90.9%+13.8% a yearPrice +66.0% | +184.0%+23.2% a yearPrice +184.0% |
| 10 years since November 21, 2016 | +206.5%+11.9% a yearPrice +135.2% | +328.5%+15.7% a yearPrice +328.5% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
JNJJohnson & JohnsonLGNDLigand Pharmaceuticals
| Price | $270.47 | $286.85 |
|---|---|---|
| Market value | $652B | $5.7B |
| Enterprise value (EV) | $679B | $6.4B |
| P/E | 40.5 | 111.2 |
| P/E, 5-year median | 21.9 | 30.8 |
| P/B | 8.0 | 6.0 |
| EV/EBIT | 38.3 | 271.4 |
| Free cash flow yield | 3.2% | 1.6% |
| Revenue, 12 months | $99.3B | $254M |
|---|---|---|
| Net income, 12 months | $16.1B | $51M |
| Free cash flow, 12 months | $20.6B | $91M |
| Earnings per share, 12 months | $6.59 | $2.30 |
| Revenue growth, year on year | 6.1% | 60.4% |
| Revenue growth a year, past | +2.7%over 5 years | +10.4%over 5 years |
| EPS growth a year, past | +14.9%over 5 years | – |
| Gross margin | 67.6% | – |
|---|---|---|
| Operating margin | – | 9.3% |
| Net margin | 16.2% | 20.3% |
| ROIC | 12.4% | 1.3% |
| ROE | 19.7% | 5.3% |
| Cash | $17.2B | $447M |
|---|---|---|
| Total debt | $44.7B | $1.2B |
| Net debt / EBITDA | 1.1 | 11.9 |
| Interest cover | 18.0× | 2.9× |
| Dividend yield | 2.0% | – |
|---|---|---|
| Dividend per share, 12 months | $5.28 | – |
| Dividend growth a year, past | +5.3%over 5 years | – |
| Buyback yield | 0.9% | 0.3% |
| Shareholder yield | 2.9% | 0.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($652B) is about 113.9 times Ligand Pharmaceuticals ($5.7B), at today's prices.
Since November 21, 2016, JNJ's price moved +135.2% and LGND's +328.5%. With dividends: JNJ +206.5% (+11.9% a year), LGND +328.5% (+15.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is 1.95% for Johnson & Johnson and none for Ligand Pharmaceuticals. Over the last twelve months they paid $5.28 and – per share.
At today's price, the P/E is 40.5 for JNJ and 111.2 for LGND. The median of the last five years was 21.9 and 30.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 20.3% for Ligand Pharmaceuticals, and the operating margin – and 9.3%. Revenue was $99.3B and $254M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.